ADDITIONAL INFORMATION 21 21.1.4 FREE SHARES (ii) achievement of the performance criteria described below no (a) Free shares granted by the Company later than July 27, 2019: – 275,000 of these free shares will be acquired upon receipt We have granted free shares (Attributions Gratuites d’Actions, or of the definitive results of the GS010 REVERSE clinical trial; AGA) since July 26, 2016. and As of the date of this Registration Document, 347,000 of the – the remaining 275,000 free shares wil l be acquired upon granted shares have been definitively acquired, including 291,000 completion of the enrol lment of 50% of the patients of a performance shares and 56,000 non-performance shares. Phase I/I I clinical trial of GS030 in RP. AGA 2016 granted on July 26, 2016 • 43,500 AGA 2016 wil l be ful ly acquired on July 27, 2018 (one year after their grant date). With the authorization of the general meeting of shareholders on May 19, 2016, the Board of Directors granted 766,000 free The AGA 2016 wil l be issued at their nominal value and wil l shares (AGA 2016) on July 26, 2016, as follows: be subject to a lock-up period of one year after their actual acquisition date. • 710,000 AGA 2016 (of which 153,000 were canceled) may be AGA 2016 granted on December 19, 2017 fully acquired by Key Managers, including Mr. Gilly, subject to the achievement of the following performance criteria no later With the authorization of the general meeting of shareholders on than July 26, 2018: May 19, 2016, the Board of Directors granted 72,500 free shares – 291,000 of these free shares were acquired at the (AGA 2016) on December 19, 2017. completion of enrollment in RESCUE and REVERSE clinical The AGA 2016 may be fully acquired by one Key Manager, subject trials; and to (i) a one year acquisition period from the date of grant and – the remaining 291,000 free shares will be acquired at the (ii) achievement of the performance criteria described below no enrollment of the first patient in a Phase I/I I clinical trial of later than July 27, 2019: GS030 in RP. • 36,250 of these free shares will be acquired upon receipt of the • 56,000 AGA 2016 were ful ly acquired in July 26, 2017 definitive results of the GS010 REVERSE clinical trial; and (one year after their grant date). • the remaining 36,250 free shares wil l be acquired upon completion of the enrol lment of 50% of the patients of a The AGA 2016 wil l be issued at their nominal value and wil l Phase I/I I clinical trial of GS030 in RP. be subject to a lock-up period of one year after their actual acquisition date. The AGA 2016 wil l be issued at their nominal value and wil l be subject to a lock-up period of one year after their actual The Board of Directors held on July 27, 2017 acknowledged acquisition date. the definitive acquisition of 347,000 free shares and decided (b) Conditions governing the free shares granted by the Company accordingly to increase the capital increase of €8,675. Free shares are granted to employees only. The beneficiary AGA 2016 granted on July 27, 2017 will definitively acquire the shares for free after an “acquisition With the authorization of the general meeting of shareholders period,” given that he/she is still within the Company at this time. on May 19, 2016, the Board of Directors granted 593,500 free Then a “retain period” is applied before shares can be disposed. shares (AGA 2016) on July 27, 2017, including: (c) Free shares holders • 550,000 AGA 2016 (of which 40,000 were canceled) may The table below sets forth the free shares granted by us to our be fully acquired by Key Managers, including Mr. Gilly, subject executive officers and directors as of the date of the registration to (i) a one year acquisition period from the date of grant and of this Registration Document: Name Grant Date Number of free shares Performance condition Bernard Gilly 07/26/2016 250,000 Yes 07/27/2017 200,000 Yes Thomas Gidoin 07/26/2016 150,000 Yes 07/27/2017 90,000 Yes Total 690,000 GENSIGHT BIOLOGICS – 2017 Registration Document– 217